Yaqrit

Yaqrit is a clinical-stage biotech pioneering a multi-target approach to advanced liver disease, built on foundational research into the gut-liver axis and systemic inflammation. Its diversified pipeline spans small molecules, advanced microbiome therapeutics, and an extracorporeal liver support device, targeting high-unmet-need indications from decompensated cirrhosis to organ failure. With a seasoned leadership team, key industry partnerships, and programs advancing into clinical trials, the company is positioned to address significant gaps in the hepatology treatment landscape. Its strategy involves intervening at different points in the disease's inflammatory cascade to both treat and prevent progression.

Multi-modal platform targeting the inflammatory cascade in advanced liver disease, including ammonia scavengers, advanced microbiome therapeutics (engineered oral adsorbents), TLR4 antagonists, and an extracorporeal liver support device.

Yaqrit operates in a competitive hepatology space dominated by large pharma in earlier-stage diseases like NASH. However, its focus on late-stage complications (ACLF, HE, decompensated cirrhosis) is less crowded. Competitors include companies developing ammonia-lowering therapies (e.g., Bausch Health's rifaximin for HE) and other investigational agents for ACLF, but Yaqrit's broad, mechanism-focused portfolio is a key differentiator.